Shares of Globus Medical (GMED) are set to plummet 18.41% in pre-market trading on Friday, following the release of disappointing first-quarter 2025 financial results and a reduced earnings outlook. The medical device maker's performance fell short of analyst expectations, raising concerns about its growth trajectory and prompting several analysts to cut their target prices.

Globus Medical reported adjusted earnings per share (EPS) of $0.68 for Q1, missing the analyst consensus estimate of $0.74 by 8.11%. This represents a 5.56% decrease compared to the $0.72 per share reported in the same period last year. The company's quarterly sales also disappointed, coming in at $598.12 million, 4.44% below the analyst consensus estimate of $625.90 million and marking a 1.41% decrease from the previous year's quarter.

Adding to investor concerns, Globus Medical cut its full-year 2025 adjusted EPS outlook to a range of $3.00 to $3.30, down from the previous guidance of $3.10 to $3.40. CEO Dan Scavilla cited softer deal closures, temporary integration-related supply-chain disruptions, and the timing of international distributor orders as factors impacting the company's recent performance. In response to the news, several analysts, including those from Wells Fargo, Jefferies, RBC, BofA Global Research, Stifel, and Canaccord Genuity, have lowered their target prices for Globus Medical stock, further contributing to the negative sentiment surrounding the company.